As studies support the hypothesis that CRH signaling pathways play a vital role in the pathophysiology of IBS, colon function and visceral perception in IBS patients may be modified through peripheral administration of αhCRH, a non-selective CRH receptor antagonist. Here, CRH is linked to irritable bowel syndrome.